Current treatments of the anxiety disorders in adults

被引:100
作者
Ballenger, JC [1 ]
机构
[1] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA
关键词
anxiety disorders; cognitive behavioral therapy; pharmacotherapy; treatments; adults;
D O I
10.1016/S0006-3223(99)00220-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The progress in developing effective treatments for the five principal anxiety disorders (ADs) in adults-panic disorder (PD), social phobia (SP), obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), posttraumatic stress disorder (PTSD)-has been rapid in the past 15 years. There are now well-controlled clinical trials documenting effective pharmacological and psychological treatments for all of these disorders, although generally the evidence is better developed for some disorders than for others. Both the pharmacological treatments and the effective psychological treatments for each disorder will be briefly reviewed. The available data for combination treatment will be reviewed and comparisons of the two types of treatment will be made. This review will contain at beast brief reviews of what the treatments involve and attempt to describe how well they work. Many studies unfortunately report only the percentage of patients who "improve" without quantifying the clinical significance of those responses. Data underlining clinical response in terms of the percentage of patients who have an "excellent," "marked, " or "moderate" response, and the percentage of patients with a "clinically significant" response will be reported whenever available. Other clinically relevant issues such as length of treatment-relapse rates upon discontinuation and side effects will be presented. As such, this article should provide a brief but comprehensive review of the treatment of these disorders in adults. (C) 1999 Society of Biological Psychiatry.
引用
收藏
页码:1579 / 1594
页数:16
相关论文
共 176 条
[41]  
DAVIDSON JRT, 1993, J CLIN PSYCHOPHARM, V13, P423
[42]   Response characteristics to antidepressants and placebo in post-traumatic stress disorder [J].
Davidson, JRT ;
Malik, ML ;
Sutherland, SN .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 (06) :291-296
[43]  
DAVIDSON JRT, 1993, AM J PSYCHIAT, V150, P1024
[44]   POSTTRAUMATIC-STRESS-DISORDER IN THE COMMUNITY - AN EPIDEMIOLOGIC-STUDY [J].
DAVIDSON, JRT ;
HUGHES, D ;
BLAZER, DG ;
GEORGE, LK .
PSYCHOLOGICAL MEDICINE, 1991, 21 (03) :713-721
[45]   Treatment of posttraumatic stress disorder with nefazodone [J].
Davidson, JRT ;
Weisler, RH ;
Malik, ML ;
Connor, KM .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 (03) :111-113
[46]  
DeMartinis NA, 1996, J CLIN PSYCHIAT, V57, P245
[47]  
den Boer JA, 1998, J CLIN PSYCHIAT, V59, P30
[48]  
DERIVAN A, 1997, M AM COLL NEUR HON
[49]  
DEVEAUGHGEISS J, 1991, ARCH GEN PSYCHIAT, V48, P730
[50]   SOCIAL PHOBIA - THE CLINICAL EFFICACY AND TOLERABILITY OF THE MONOAMINE OXIDASE-A AND SEROTONIN UPTAKE INHIBITOR BROFAROMINE - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY [J].
FAHLEN, T ;
NILSSON, HL ;
BORG, K ;
HUMBLE, M ;
PAULI, U .
ACTA PSYCHIATRICA SCANDINAVICA, 1995, 92 (05) :351-358